A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points

Haematologica. 2006 Mar;91(3):415-6.

Abstract

Serial analysis for the activating JAK2(V617F) mutation performed in 44 patients with myelofibrosis with myeloid metaplasia showed no interval change in 88% (22/25) of patients over a median interval of 18.6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or leukemic transformation.

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Humans
  • Janus Kinase 2
  • Longitudinal Studies
  • Mutation*
  • Phenylalanine / genetics
  • Primary Myelofibrosis / enzymology*
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / pathology
  • Protein-Tyrosine Kinases / biosynthesis
  • Protein-Tyrosine Kinases / genetics*
  • Proto-Oncogene Proteins / biosynthesis
  • Proto-Oncogene Proteins / genetics*
  • Up-Regulation / genetics
  • Valine / genetics

Substances

  • Proto-Oncogene Proteins
  • Phenylalanine
  • Protein-Tyrosine Kinases
  • JAK2 protein, human
  • Janus Kinase 2
  • Valine